In Vitro Activities of LY303366 against Clinical Isolates of Candida spp., Cryptococcus neoformans and Aspergillus spp..
- Author:
Kyungwon LEE
1
;
Dongeun YONG
;
Hee Bong SHIN
;
Young Ah KIM
;
Yunsop CHONG
Author Information
1. Department of Clinical Pathology, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:In Vitro ; Original Article
- Keywords:
Antifungal activity;
LY303366;
C. albicans;
C. neoformans;
Aspergillus spp.
- MeSH:
Amphotericin B;
Antifungal Agents;
Aspergillus*;
Candida*;
Cryptococcus neoformans*;
Cryptococcus*;
Fluconazole;
Flucytosine;
Fungi;
Humans
- From:Korean Journal of Infectious Diseases
2000;32(4):274-279
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Fungal infection became more prevalent with the increase of compromised patients, requiring less toxic potent antifungal agents. LY303366, a new semisynthetic antifungal agent of echinocandin class, was reported to be active against Candida spp. and filamentous fungi. METHODS: In vitro activities of LY303366 were determined against clinical isolates of fungi by NCCLS broth microdilution test using RPMI 1640 medium. RESULTS: MIC90s of LY303366 were 0.03 microgram/mL for C. albicans, 2 microgram/mL for C. parapsilosis, 0.12 microgram/mL for C. tropicalis. LY303366 was more active against C. albicans and C. tropicalis than amphotericin B, 5-fluorocytosine, or fluconazole. It was less active than other agents against C. neoformans. MIC range of LY303366 against Aspergillus spp. was 8->16 microgram/mL. CONCLUSION: Very high in vitro activity of LY303366 against recent clinical isolates of Candida spp. including fluconazole resistant ones, suggests its usefulness for the treatment of candidal infections.
